19
1
49
2
8
1b
1d
18
33
25
7
4
1
b
1d
2 29
1d
25
Dorothee Herlyn, DVM.
78
25
7
4
1
b
1d
46
Contact information
42
4
3
3
1d
42
The Wistar Institute
35 3601 Spruce Street
Philadelphia, PA 19104
26
35 3601 Spruce Street
Philadelphia, PA 19104
30
Office: (215) 898-3962
30
91
30
Email:
dherlyn@wistar.upenn.edu
12
dherlyn@wistar.upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
98 Search PubMed for articles
84 Primary Work Website
42 Immunology graduate group facutly webpage.
c
4
b
1f
98 Search PubMed for articles
84 Primary Work Website
42 Immunology graduate group facutly webpage.
c
13
Education:
21 b D.V.M. c
37 University of Munich, Germany , 1970.
21 a D.Sc. 17 (Physiology) c
37 University of Munich, Germany , 1975.
c
3
3
3
3
8f
Permanent link21 b D.V.M. c
37 University of Munich, Germany , 1970.
21 a D.Sc. 17 (Physiology) c
37 University of Munich, Germany , 1975.
c
2 29
21
1e
1d
24
5e
8
1d Cancer immunotherapy
8
19 Research Summary
8
2dc Our laboratory is developing cancer vaccines that are being evaluated in animal models for their protective activity against tumors before they are administered to cancer patients. The vaccines are composed of antibodies mimicking tumor antigens (anti-idiotypic antibodies) or the antigens expressed in viruses (recombinant adeno- or vaccinia-viruses) and are selected based on their high probability of inducing both humoral and cellular immune responses in patients. The animal models we have developed for preclinical evaluation of the vaccines closely mimic the condition in cancer patients. In other studies which have reached clinical trials, we are evaluating the vaccinated patients' immune responses to their tumors.
e 29
27
Description of Research Expertise
24 Research Interests8
1d Cancer immunotherapy
8
19 Research Summary
8
2dc Our laboratory is developing cancer vaccines that are being evaluated in animal models for their protective activity against tumors before they are administered to cancer patients. The vaccines are composed of antibodies mimicking tumor antigens (anti-idiotypic antibodies) or the antigens expressed in viruses (recombinant adeno- or vaccinia-viruses) and are selected based on their high probability of inducing both humoral and cellular immune responses in patients. The animal models we have developed for preclinical evaluation of the vaccines closely mimic the condition in cancer patients. In other studies which have reached clinical trials, we are evaluating the vaccinated patients' immune responses to their tumors.
e 29
23
147 Li, J., Pereira, S., VanBelle, P., Tsui, P., Elder, D., Speicher, D., Deen, K., Linnenbach, A., Somasundaram, R., Swoboda, R., and Herlyn, D. : Isolation of the melanoma-associated antigen p23 using antibody phage display. J. Immunol. 166: 432-438, 2001.
1a1 Staib, L., Birebent, B., Somasundaram, R., Purev, E., Braumüller, H., Leeser, C., Küttner, N., Li, W., Zhu, D., Wunner, W., Speicher, D., Beger, H-G., Song, H., Diao, J., and Herlyn, D. : Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastrointestinal carcinoma patients. Int. J. Cancer 92: 79-87, 2001.
ec Guerry, D., and Herlyn, D. : CD4+, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells. Int. J. Cancer 85: 253-259, 2000.
17f Basak, S., Eck, S., Gutzmer, R., Smith, A.J., Birebent, B., Purev, E., Staib, L., Somasundaram, R., Zaloudik, J., Li, W., Jacob, L., Mitchell, E., Speicher, D., and Herlyn, D. : Colorectal cancer vaccines: anti-idiotypic antibody, recombinant protein, and viral vector. Ann. N.Y. Acad. Sci. 910: 237-253, 2000.
189 Li, W., Berencsi, K., Basak, S., Somasundaram, R., Ricciardi, R.P., Gonczol, E., Zaloudik, J., Linnenbach, A., Maruyama, H., Miniou, P., and Herlyn, D. : Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by recombinant adenovirus inhibits growth of established CRC cells in mice. J. Immunol 159: 763-769, 1997.
2c
7
1d
1f
Selected Publications
1cb Somasudaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S., Monos, D., Peritt, D., Marincola, F., Cai, D., Birebent, B., Bloome, E., Mastrangelo, M., and Herlyn, D. : Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-b1. Cancer Res. 62: 5267-72, 2002.147 Li, J., Pereira, S., VanBelle, P., Tsui, P., Elder, D., Speicher, D., Deen, K., Linnenbach, A., Somasundaram, R., Swoboda, R., and Herlyn, D. : Isolation of the melanoma-associated antigen p23 using antibody phage display. J. Immunol. 166: 432-438, 2001.
1a1 Staib, L., Birebent, B., Somasundaram, R., Purev, E., Braumüller, H., Leeser, C., Küttner, N., Li, W., Zhu, D., Wunner, W., Speicher, D., Beger, H-G., Song, H., Diao, J., and Herlyn, D. : Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastrointestinal carcinoma patients. Int. J. Cancer 92: 79-87, 2001.
ec Guerry, D., and Herlyn, D. : CD4+, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells. Int. J. Cancer 85: 253-259, 2000.
17f Basak, S., Eck, S., Gutzmer, R., Smith, A.J., Birebent, B., Purev, E., Staib, L., Somasundaram, R., Zaloudik, J., Li, W., Jacob, L., Mitchell, E., Speicher, D., and Herlyn, D. : Colorectal cancer vaccines: anti-idiotypic antibody, recombinant protein, and viral vector. Ann. N.Y. Acad. Sci. 910: 237-253, 2000.
189 Li, W., Berencsi, K., Basak, S., Somasundaram, R., Ricciardi, R.P., Gonczol, E., Zaloudik, J., Linnenbach, A., Maruyama, H., Miniou, P., and Herlyn, D. : Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by recombinant adenovirus inhibits growth of established CRC cells in mice. J. Immunol 159: 763-769, 1997.
2c